Producer
Novo Nordisk
World's largest insulin manufacturer. Controls ~33.7% of global diabetes care market; ~45% of human insulin. Operates the world's largest insulin production facility in Kalundborg, Denmark (produces ~50% of global insulin supply). Dominant in GLP-1 drugs (Ozempic/Wegovy); FY2024 revenue DKK 232B. Uses both E. coli and yeast fermentation.
2
Inputs supplied
1
Goods downstream
3
Facilities
0
Stories
What they make
2 inputs Novo Nordisk supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Novo Nordisk makes, pick one to see the full supply chain.
Where they make it
3 facilities
Novo Nordisk - Clayton, North Carolina USA →
USOral semaglutide API (Rybelsus); majority of oral tablet semaglutide manufactured here; $4B+ expansion for GLP-1 production
Novo Nordisk - Kalundborg, Denmark (API) →
DKPrimary injectable semaglutide API production (all Ozempic/Wegovy injectable API); worlds largest insulin production site also; $6.1B expansion investment 2024; sole source for injectable semaglutide API globally
Novo Nordisk Kalundborg Manufacturing Complex →
DKKalundborg, Denmark · fermentation_and_api
World's largest insulin production facility. Produces approximately 50% of the global insulin supply. Operates massive E. coli and yeast fermentation capacity. Single-facility failure here would be a global insulin supply crisis.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Insulin (World #1 — ~45% Global Market)
30%GLP-1 Drugs (Ozempic + Wegovy + Victoza)
55%Rare Disease + Hemophilia
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2023
Novo Nordisk (Bagsværd, Denmark) was founded in 1923 — exactly one year after Frederick Banting, Charles Best, and John Macleod at the University of Toronto announced the discovery of insulin (January 11, 1922) and first successfully treated a diabetic patient (January 23, 1922, Leonard Thompson). Thorvald Pedersen and his brother Harald Pedersen founded Novo in Copenhagen in 1923 to produce insulin from pig pancreases purchased from Danish slaughterhouses. A century later, Novo Nordisk has become the most valuable company in Europe (surpassing LVMH by market capitalization in 2023) — not primarily because of insulin, but because of its GLP-1 receptor agonist drugs semaglutide (Ozempic for diabetes, Wegovy for obesity). The same company that has treated diabetes with insulin since 1923 now sells the weight-loss drugs that may reduce Type 2 diabetes prevalence over time — potentially partially cannibalizing its own insulin business. Novo Nordisk simultaneously holds the top position in the disease (insulin for diabetes management) and in a drug that targets the condition's root causes (GLP-1 for obesity-driven Type 2 diabetes). No other pharmaceutical company in history has been simultaneously the leader in managing a disease AND in reducing that disease's underlying risk factor.
Novo Nordisk A/S ↗Origin2023
Novo Nordisk A/S has a unique corporate governance structure: approximately 76% of its voting rights are controlled by the Novo Nordisk Foundation — a Danish non-profit foundation that uses Novo Nordisk dividends to fund biomedical research, global health initiatives, and social programs. The foundation-company structure was created in 1948 when two competing Danish insulin companies (Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium) merged to form Novo Nordisk; the merger was structured to place control in a foundation to ensure the mission of providing affordable diabetes care was maintained above pure profit maximization. As Ozempic and Wegovy transformed Novo Nordisk into one of the world's most valuable companies (briefly exceeding the entire Danish GDP in market capitalization in 2023-2024), the foundation's dividend income grew dramatically — making the Novo Nordisk Foundation one of the largest private charitable foundations in the world by asset value. A foundation created to protect diabetes medicine affordability is now one of the world's richest charitable institutions because the same medicines became the most commercially successful pharmaceutical products ever.
Novo Nordisk A/S ↗